Chapters Transcript Video Expanding cancer treatment options through interventional radiology The dose of radiation we can deliver is extremely high compared to conventional radiation because we're not going through skin or anything there's no structures to protect and we're also delivering it locally inside of the vessels going just to the tumor, um, and so we're talking like for example like 5 400 gray, 500 gray versus like usually it's 50, um, and so we're able to get a lot more curative, um, with lesions that are bigger. Hi, I'm Lindsay Carrillo, System Director of Business Development at UCI Health. Hi, I'm Doctor Sunil Verma, associate Chief Medical Officer for ambulatory at UCI Health and an otolaryngologist. Welcome to Physician Huddle by UCI Health. Today we're joined by Doctor Nadine Abijadeh, Chief of the Division of Interventional Radiology and Professor of Radiological Sciences at the UC Irvine School of Medicine. Welcome. Thank you. Tell us about your journey to come here to UCI Health, including some time spent at the National Institutes of Health, right? Yeah, so I joined UCI in 2015, so it's already been 11 years. Uh, before that, I was at the NIH for about eight years. Um, you know, it's, it's kind of been a long journey. I actually did most of my training in Canada, uh, and I initially wanted to be a surgeon. Um, and I did a rotation like during med school that wasn't an actual rotation was kind of like a friend of the family like was like, oh I know you wanna go to surgery, like come follow me, uh, so I had no, uh, responsibilities. It wasn't like during my official rotations was kind of just a summer thing, uh, but to the residents and. Surgery that summer we're quitting surgery and because it was like too taxing and then some of the surgeries were kind of he was a GI surgeon so there were more on the messier side and I thought that like this isn't delicate or precise enough for me so I I kind of switched to go into internal medicine. But during my actual surgical rotations, there were two patients that nobody could do anything for, and they're like, send them to IR and then IR fixed the issue. One of them was this guy who would keep coming back to the ED with a, you know, he'd have hematuria, so he'd have blood in his urine that would clog up his foley and his bladder, and they'd have to come into the ED to wash him every couple of days and IR embolize the tumor, and at least he got 8 months of like. You know, not having to go to the ED, he did end up passing, but it was just so nice to see like that it improved his quality of life. And so I was like, oh, I don't know what this is. I'm just gonna go explore it. But I even took the rotation after the match and so I matched into internal medicine and then during my rotation in IR I'm like, oh, this is what I want to do. And that's how I switched into IR. Um, and then one of my attendings who trained me was kind of the mentor that, you know, inspired me to go into IR actually trained at UVA. And so I ended up by doing my fellowship at UVA. I'm from UVA, you know, super close to NIH and a lot of connections in terms of research, and I was in love with the research, so I ended up by. Going to the NIH for 8 years. So when someone's at the NIH or when you were at the NIH, was it both clinical and research, or was it more one than the other? It was both. Um, the NIH has a clinical center, so there's actually a hospital inside, but nobody, there's no ED. It's like literally you only go there if you're on. Your own protocols or somebody else's protocols, but everybody there is on some research protocol. Uh, it's really cool because they accept patients from all over the country, even all over the world, and the care there is at no cost to the patients, uh, as long as you know they have to be on the trial. Oh, that's incredible. I mean, it's funny you talk about like, well, just send them to AIR maybe they can do something about it. Like people even describe what you do is like, it's magic, like no one really understands it, but we'll just send them there and then they'll just magically get better. But tell us a little bit more like why, why does it have that reputation? I think it's because it started off um by like kind of patients that had no other options and a lot of like actually IR solutions to the all of procedures were like patients that everybody else is like OK well there's not much we can do for you uh so if we look for example when the the person credited with being the father of IR um. Is uh his daughter, uh, and actually like he, he, they used to do angiographies, but then he started to like there was a patient that was scheduled for an amputation and he started with his dilators to like take out the atherosclerotic plaque which shaved the person's leg. And that's the first kind of, that's how IR was born. Um, if you look at like HCC, which is interventional oncology, a lot of that is, is started off in HCC. The trials were like for patients who had failed every other option. So a lot of times the patients that are sent to us are kind of like, have exhausted a lot of the other stuff, and they're like, out of options. Yeah, my first experience with it was in residency, but it was honestly mostly asking for biopsies, you know, uh, drain placements, that sort of thing. But my understanding, that's, that's not even the tip of the iceberg for everything that an interventional radiologist does, that's correct, especially at an academic medical center. That's correct, yeah, a lot of, um, IR is very heterogeneous, and yeah, anytime. You know, if you look at the definition, it is image guided interventions in a way, so anything you do with like a needle or, or a catheter and imaging could be classified as IR, um, and it did start off a lot of it with the diagnostic parts like biopsies, ports, drains, etc. but has moved on to therapeutic stuff, especially in the academic centers where, you know, IRS of clinics and then we see patients and then we do more advanced procedures. Let's talk about therapeutics. Can you speak to a little bit about how interventional radiologists participate in the care of patients with pancreatic cancer? Yeah, so we have actually, this is a new area for IR that we're expanding into, um, and we have here a trial and then there's several, um, standard of care therapies. Um, the trial that we have at UCI involves putting a laser into the arteries of patients who, so. Backing up a little bit, a lot of patients with pancreatic cancer are not surgical, um, but surgery is really what makes a difference in overall survival at 5 years, um, and so if we could make patients surgical, we could actually improve their overall survival. Um, part of the reason why they're not surgical is where the cancer is, it surrounds vessels that can't be removed. The SMA or celiac. And so what we do is we go in, we inject a drug that is light sensitive, and then we put a balloon that has a laser inside of it. We inflate the balloon and then activate the laser which activates the drug to kill the tumor around the vessel. So then the surgeons are able to remove the rest of the tumor and then get the patients to. Resection and ideally R zero resection. So then how long after you do this laser treatment do you actually see results for the patient and how do you monitor that? Is that with subsequent imaging or tumor markers? So we have tried imaging. Um, it's just, it's really hard to image the pancreas in general. Uh, what's been happening. 2 weeks after that they've been going to the OR and they're actually getting biopsies of the areas around the vessels that could stop them from having the R0 margin. If those are negative, then they proceed with the surgery. So that quickly within a couple of weeks it takes effect on the actual tumor itself. And so you said this is in a trial. So what is the general inclusion criteria for the trial? Is it based off of the where the disease is in the pancreas or the tumor bulk or peritoneal spread? A peritoneal spread is actually an exclusion unfortunately. Um, it has to be locally advanced, which 50% of patients will present with locally advanced. Some of them 15% are upfront resectable, uh, but 35% are not, and a lot of it has to do with, it has to be in the head or neck or kind of like that area where it surrounds the vessels. So your tumor boards essentially you have the medical oncologists who we've had on here before, you have surgeons as well, and you have yourself. And then as a group, I'm assuming you decide based off of the all those factors that you just mentioned. Yes, so all the patients are reviewed at tumor board. There's also radiation oncology at tumor board, and we make sure, so the surgeons look at it and they're like, oh yeah, if we can clear the vessels, then they could be potentially surgical or not, and depending on that, that's how we go. You mentioned some therapies, um, NanoKnife, there's other things where you're literally just pushing chemotherapy directly into the tumor. How does that fit in to something like this laser light therapy, like how much of it is sort of standard of care now and how much of it is like Experimental or we're just trying some new things here. Um, so in terms of the, uh, the, the laser therapy that, that's still in trial, um, the, the, the pushing the chemotherapy into the tumor, it's called transarterial microperfusion, so TAMP for short, um, and that is approved by the FDA. There is, um, a randomized controlled trial in pancreatic cancer. Um, and there's also NanoKnife which, uh, but both of those are kind of a little later for patients who are not operable and confirmed like can never be operable kind of thing, um, and so although we are opening a trial to try to see if patients have had chemo radiation were not operable, um, can we still make them operable by pushing the chemo locally and shrinking the tumor. So how do you develop trials like this? I mean, my understanding is pancreatic cancer isn't all that common, and you just mentioned like 2 or 3 trials for patients, right? So how do you develop an end that's big enough to understand if these um technologies are, are substantial enough to actually make a change in the way we treat our patients. So a lot of these are like, you know, collaborative, so we collaborate with the surgeons, oncologists, etc. like all these are, are very multidisciplinary. Um, I think part of it is we have a big referral base for pancreatic cancer and, and that's because, you know, we have the expertise and so then we have good results, so then that gets more patients and it kind of turns into like a. A flywheel and then tell me a little bit about when you're doing these treatments. Are these done under general anesthesia? Are patients monitored afterwards in the hospital, um, or are they going home the same day? Seems like, I mean, these are seemingly pretty, um, intense treatments. Yes, so for the laser therapy, which is experimental, they are staying in-house and that's because the light. The drug that we inject that's light sensitive makes them a little uh sensitive to light and so we actually put them in a dark room yeah I turn them into vampires that's the joke. Uh, for a temp that it is done under general anesthesia, the, the chemo profusion, but they can leave the same day. Um, the NanoKnife, we do keep them for 24 hours, but they leave like the next day, 99% of them. Sorry, can you give us a little more detail about NanoKnife? So NanoKnife is when, um, there's a lesion that's kind of discrete, usually like around 3 centimeters or so. We can put needles that surround it and then between. Each pair of needles, there's electrical volts, about 3000 volts, so it has to be done under genetics use it for that reason, um, that, you know, are go between the needles that basically electrocute the lesion, but they keep, it doesn't deform the extracellular matrix, so you preserve like architecture of the pancreatic ducts and vessels that you don't want to damage. So this catheters passed through a blood vessel. Into and then the needle is passed through the blood vessel into the tumor. No, the nano knife is just directly percutaneous needles. OK. The transarterial microperfusion is a catheter that has a double balloon and in between the two balloons you perfuse, and then the experimental one is another. through the vessel. Wow, so there's multiple ways that you are attacking literally the pancreas or the tumors in this area. Yeah, OK, so now I think I know why you have this magical reputation because now we've talked about lasers and electrocution, right, vampires, all the best stuff. And how do you, how many physicians out there are aware of this, you know, this level of technology, if you will, or this level of um treatment, um. Because at least when we were in medical school, this was certainly wasn't the standard of care. No, and I actually recall, um, funnily enough, not a lot of people know this actually, um, when I was at the NIH my department chair organized that I meet a couple of physicians. One of them was so excited to meet me, uh, thinking I was IR, um, and talking to him like there was just like a complete disconnect and he's like, wait, IR means infrared, right? You're an infrared expert. I'm like. Uh, no, not yet. And I couldn't get out fast enough of the meeting. So, um, a lot of times, a lot of people don't know everything IR can do, um, and I mean if like it's constantly evolving as well and so, um, you know that that's partly why we just say like call us, talk to us, we're well. Right. Brainstorm and some new technology, some sci-fi thing. So let's talk a little bit about liver cancer, um, and what your chemo embolization technologies can do. Uh, can you expand on that a little bit? So chemo embolization was actually one of the first things how IRs got into oncology, um, and initially it was in in HTC where it was compared to best standard of care and randomized control trials that chosen improves overall survival. Um, this has kind of grown and now is part of the, you know, standard of care, um, but more recently. people have started doing radio embolization, which is where we go in and we infuse tiny little beads that have radiation on them. The dose of radiation we can deliver is extremely high compared to conventional radiation because we're not going through skin or anything. There's no structures to protect and we're also delivering it locally inside of the vessels going just to the tumor. Um, and so we're talking like, for example, like 5 400 gray, 500 gray versus like usually it's 50, um, and so we're able to get a lot more curative, um, with lesions that are bigger. Um, and one of the things we're looking at at UCI is, um, one of the things that's a problem with chemo EO, which is why people start to look at how to improve it, is that, uh, the cells that are resistant to hypoxia are the ones that survive, and they tend to. Generally be more aggressive because what chemoembo does is you put chemo and then you shut the blood vessels, uh, but there are cancer stem cells and some stem cell and some cells, cancer cells that are resistant to hypoxia, and those are the most aggressive ones and they tend to survive chemoembo so then you're kind of naturally selecting the most aggressive cells, um, so we have a trial where instead of we're leveraging that and we're putting a hypoxia activated drug. Instead of the regular like chemo agents and then embolizing so that you know the cells oxygen drops and that activates the drug to finish off even the ones that are resistant to hypoxia um we are exploring this and actually again patients who have failed first line. At least one line of uh immunotherapy, um, so as you know, second line HCC is not much standard of care right now. Um, the standard, the response rate for immunotherapy is about 25%. That's with Etazobab or Durvarami or any of them. We're seeing about a 55% response rate in second line. So patients, uh, when we're combining this, what we call it TPZ or TAIT, um, with immunotherapy, uh, compared to, uh. So, so you have these little beads that have radiation in them. Are they activated? Are they active as you're actually putting them in? Or do you, do they go through and activate? OK, so they're active when you put them in, and then how long do they stay active for? So the radiation is decaying like even that's why it's very regimen they're decaying as like we're put, so we, we actually time it so that we have the radiation level we need as we're injecting, um, but they will stay active the 1st 3 days. Most of the radiation leeches off by 11 days are back to back rubbing like it's nothing was there. But they've done what they needed to. And why pick the liver? I mean, are there other organs where this has been tried out before? So they're now trying out radioembolization in the brain, um, and they're also trying it. I think there's like some, again, very early stages in prostate. Uh, the reason why it's in the liver. It's because the liver is a very special organ, the only organ with a dual blood supply, so hepatic artery and portal vein, and actually normal liver gets most of the blood supply from the portal vein, but the tumors get 85 to 90% of their blood supply from the hepatic artery, and we're going in the hepatic artery. So the liver most naturally lent itself to this. Let's talk a little bit more about the liver. I think you're doing some other things there as well. We talked about liver perfusion and how is that different from some of the other things that we've already discussed. So liver perfusion is, um, so it started off with patients who have um Melanoma, um, so especially uveal melanoma, so it's different from every type of melanoma. So regular melanoma responds pretty well to immunotherapy, but uveal melanoma, uh, 50% of those patients will have liver mats. Uveal melanoma is different, so it. Unlike regular melanoma, it does not respond to immunotherapy. 50% of patients will develop liver, uh, metastasis and usually have like a big, uh, tumor burden, um, and, uh, there's not a lot of options that work. In fact, once you failed the first line, the response rates are about 11%, um, so what we do is we go in, we isolate. The veins that drain the liver with two big balloons, uh, we go in from the hepatic artery, infuse very high doses of melphalan that go through the liver and then are washed out between in that catheter between the two balloons are taken into extra corporal circulation. The melphalan is cleared and then returned the blood is returned back into the body, um. And so you're able to like, you know, deliver very high doses of melphalan but like nothing's and nothing else gets outside of there because you've you've taken advantage of this blood supply, yes, and, and we've isolated the liver, taken it, and then it's cleaned by filters like with through extra corporal circulation. I think you're a mad scientist. I did not invent that one. Is the majority then of, of the field and really turning towards these intraabdominal oncologic, uh, cases, if you will. Yeah, but so there's also like developments and I'm specialized a lot in the abdomen, but there's a lot of developments happening in MSK and a musculoskeletal, a lot of pain interventions, and then some um orthopedics, and one of my colleagues does these procedures called with a luminos where like they can fixate percutaneously like fractures in the pelvis, um, and they do them in conjunction with orthopedics, um, but like so. You know, it's a little bit moving everywhere, um, and you can kind of see a little bit of a division in IR. There's some people who are still in kind of, you know, diagnostics and the smaller procedures and the community center like biopsy sports, and then there's the more advanced kind of uh. Procedural. So the advanced proceduralists like yourself really thrive in a place like this with high volume, a number of other specialists around to provide patients also support, um, and to be able to provide patients, you know, a number of different choices. So it's not just one treatment fits all. So what are you most excited about? What's kind of coming up on the horizon? It sounds like it can almost be anything. Let me go back. How, how stressful is all this? Like, like, legitimately to be able to be doing these things where you have a patient on the table, you're stopping blood supply in the liver. Things are going in, it's circulating out. You're delivering chemotherapy. You're delivering radiation. I mean. How, how most of the folks, I mean, my wife's a radiologist in a lot of ways she went into it to not be doing medicine, but you're doing a ton of medicine and surgery at the same time. So tell us about the stress level for this. No, I mean, it's definitely, it's stress, but at the same time it's very rewarding, just kind of like every other surgery. It's so I guess it just depends on, on. The kind of personality people have, but yeah, it's definitely stressful. It's definitely taken out of our comfort zone, um, even for me, right, when I trained, one of my attendings said like, whatever you do, never touch the pancreas. Yes, it's a very angry og organ. If you get necrotizing pancreatitis, it's very, very bad. And here I am like poking it, lasering it, whatever, so it's like a lot of stuff that like, you know, even prescribing intraarterial gemcitabine or intraarterial malphalan and putting in those orders like we've had like 7 meetings with Epic about that and so it's like stuff that's like normally radiologists don't do but um you know again this is the difference between like um the advanced IR and then the yeah you're like an oncologist but like on steroids to your point right like you're giving this medication. But not just infusing it, you're targeting it, you're doing it in high dosage, you're monitoring the patient, then you're taking it out of the body, you know, all, all the whole time you don't have the abdomen open to do any of this. Surgery with no cuts and yeah, radiation oncology radiation is wild. That's, that's, yeah, that's a very new appreciation for all the things that you're able to provide for our patients. So, what's on the horizon? What are you excited about? What are some of the newer things that you're hearing about or thinking about, dreaming about? Um, I mean, I think, you know, it just keeps expanding every day. Um, you know, I'm very excited about the, the VTP trial. I'm also excited about, so the, the TPZ, which is the hypoxia drug combined with the embolization with nivolumab for, for liver cancer patients who don't really have a lot of options, is about to move to the phase 3, I'm also, um, you know, for example, the liver perfusion where we infuse the drugs where we have a trial that's gonna open with breast cancer, um, on that with Doctor Lavasani, um, so it's there's a lot of like, um. You know, it's hard to say, yeah, and you've still been able to maintain your research chops from the NIH while being here. It sounds like there's no slowing down of any of the research or trials that you're doing. No, no, it's a lot of fun, yeah. So, you mentioned a lot of patients do find us and, you know, obviously, you have a stellar reputation and people understand the team and what they can do here, but, you know, You mentioned in sort of a misunderstood field, maybe because you do so many things, not everyone understands everything that IR could do, but, you know, to like a a community practicing oncologist or, you know, what kind of pointers would you give them or what should they think about if they are considering a patient who should come to IR? I, I think even if they don't sometimes consider a patient should come to IR there's no harm in asking, uh, because I feel sometimes that there's missed opportunities where you see patients that could have gotten an IR treatment that was simple where they got like other therapies that didn't work as well. Um, just recently I had a patient, for example, that had a single lesion, um, of liver cancer HCC that we could have done a radio embol easily on, but they had been on, on systemic therapy, um, they were not responding to systemic therapy and then also like had a lot of adverse events and ended up. Being hospitalized 3 times and so I think you know ended up getting a second opinion and then being referred to me but so I think I would say like if you know if you think somebody can put a needle in it refer to IR and then we'll I like that that's really easy to remember and and for folks that maybe are outside the system. Is it possible to refer a patient in for evaluation, but then if you can't do anything, send the patient back and have them receive all the treatment perhaps with a referring doctor in a place maybe they're more comfortable or closer to home or something of that nature. Oh yeah, we definitely do that. We also like there are patients that have combination treatments. A lot of, as I said, a lot of IR is also like multidiscipline. In combination and you know a lot of the oncologists I work with like text me all the time and we communicate directly and yeah we will refer we'll send like if it's they need like a procedure and systemic therapy well you know they can have the systemic therapy from the oncologist who refer them and do the procedure. I think that's important for for uh for our physicians to know. But it sounds like it's really important sort of the order that these things are done, because if you have a chance to get in there before other things have been damaged or taken place, wow. Is, how do you, uh, how do all of you learn about this? Is it through the on the oncology meetings? Is it through interventional radiology meetings? Seems like the field is moving very fast. How does somebody keep up with what the standard of care is? Uh, do you almost have to be a member of both of, all of the societies to keep up with everything? Um, yeah, so there's a Society for Interventional Oncology, uh, there's Society of Interventional Radiology, and then there's ASCO, and I'm actually a member of all three. Uh, because you kind of, yeah, it does move very fast, and I feel also like if you don't know what the oncologists are doing, then you can't really be relevant when you're talking to them about what you can offer. You seem very fluent, yeah, exactly, in, in what the oncologist can do, especially since you have to partner with them so closely. Yeah, wow, that's great. Well, thank you both so much for being with us today. Thank you for having me. It was a pleasure. This has been Physician Huddle by UCI Health. Thank you for joining us. This was an episode of the Physician Huddle podcast by UCI Health, produced by Brett Shaheen, Angelica Yubi, and Victor Ting. For more episodes, information on clinical trials at UCI Health, or to refer a patient, view the show notes or visit clinicalconnection.UCIhealth.org. Created by